Agent for treatment of enteritis in animals

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex


The invention relates to agriculture, in particular to veterinary medicine and can be used in animal husbandry as feed additive for treatment of digestive disorders in animals and birds.

Known antibacterial agent from the group of fluoroquinolones is enrofloxacin used to treat Pets with bacterial infections, for internal (through the mouth), and injection applications.

A disadvantage of the known device is the lack of non-specific stimulant (tonic) of the action of the animal organism and the presence of negative action, which is manifested in the disruption of cartilage in young animals. When using enrofloxacin strictly prohibited concomitant use of nonsteroidal anti-inflammatory drugs, macrolides and tetracyclines. Contraindication to the use of the drug is also the detection of pathogenic strains of bacteria that are resistant to enrofloxacin.

Closest to the claimed remedy for the treatment of bacterial enteritis (colibacillosis, salmonellosis, necrotic enteritis and other) animals are drugs for oral (internal) dose on the active substance 2.5-5 mg/kg, 1 time a day, 3-5 days: "Enroflon®-10% solution for oral use, containing in 1 ml 100 mg Enraf�of oxazine and auxiliary substances: potassium hydroxide, benzyl alcohol, water, manufacturer: LLC "VIC - animal health", Russia, registration number PVR-2-2.9/00089 (cited: Medicinal products for veterinary use in Russia. Directory "Vidal expert". - M.: Attraversare. - 2013. - P. 360-361); "Enroflox in 1 ml 100 mg enrofloxacin and auxiliary substances: potassium hydroxide, benzyl alcohol, purified water, manufacturer INVESA, Spain, registration number PVI-2-3.5/00438 from 24.02.11 (cited: Medicines veterinary use in Russia. Directory "Vidal vet". - M.: Attraversare. - 2011. Pp. 419-420). All of these analogues are summarized by the similarity in that their solvents have high alkalinity (pH=9,5-11,5). In other sources - "Injection or infusion solution of enrofloxacin" (patent RF №214722, filing: 28.12.1995) and "Treatment of mastitis by using enrofloxacin (patent RF №2413514, applying 28.10.2005), which is predominantly acidic form of complex solvents.

It is known tool for the prevention of animal diseases by raising nonspecific resistance and accelerating growth under the General title "humates", derived from natural organic raw materials (coal, peat, sapropel) by alkaline hydrolysis, is used as a feed additive, non-antibiotic properties.

Blueblack to the claimed means is "Guvitane" - liquid product of alkaline hydrolysis of peat containing humic substances used in animal feed additives to enhance their disease resistance by enhancing the processes of digestion, normalizes metabolism, binding of toxins in the gastro-intestinal tract (TU 9283-00256462103-2010. Manufacturer LLC "Russ", Voronezh, 394088, 97). A method of producing and applying humanidades product (alkali hydrolysate of sapropel) in anemia of calves in combination with transcranial electrical stimulation (Russian Federation No. 2392945, application: 2008130210/13, 21.07.2008).

The lack of Guvitane and alkaline hydrolysate of sapropel is the complete absence or the presence of weak antibacterial action on pathogens, causing enteritis.

However, each of the above agents used for animals separately, and was not determined by their joint role in the treatment of animals with bacterial enteritis.

The aim of the invention is to provide a novel means for the treatment of bacterial enteritis in animals having anti-microbial and non-specific stimulating effect and for reducing death, disease severity, and the duration of treatment (not less than 10%).

The technical result is used to ensure the improvement of results of treatment of animals with enteritis, exp�jaydees to reduce the duration and severity of the disease, reducing the number of relapses and the value of the damage avoided from disposal of animals.

The technical result is achieved by the combined expression of mutually reinforced therapeutic properties of the components and mutual funds eliminate the disadvantages of each component, which is impossible by the separate application of each component.

The distinctive features are that to achieve better therapeutic action of internal (oral) use with liquid feed enrofloxacin enteritis in animals it is dissolved in an alkaline solution of humates.

The essence of the proposed tools is that making money is by obtaining a solution of the antibacterial component of enrofloxacin (from 0.2 to 1.0 wt.% in an alkaline solution of humic substances (from 0.1 to 0.5 wt.%) sapropel (peat). Preferred alkaline solutions due to the fact that the enteritis recorded mainly in young animals (except enterotoxaemia piglets) in the diet which contain easily fermentable to lactate (lactic acid) lactose, manifested in the form of "acid catarrh of the bowel". For optimal pH is applied to the base (NaOH, KOH) and acid (succinic acid), to prevent crystallization of the solution used propylene glycol (1,2-propandiol). Cu�IU, succinic acid in the form of salts (succinates) and propylene glycol (dihydric alcohol) provide buffering environment in the gastro-intestinal tract, and imbibing, contribute to the normalization of energy metabolism, participating in the cycle (metabolism) tricarboxylic acids, thus preventing the development of metabolic acidosis. The combination of these properties offer the means provides increased therapeutic efficacy as a result of simultaneous complex influence of the components means on the patient's body of the animal and of the disease, manifested in the acceleration of the recovery of animal health and reducing the possible side effects of enrofloxacin. This reduces production costs: instead of producing two separate alkaline solutions of enrofloxacin and humates offers a simplified technology of obtaining one means by dissolving the powder substance enrofloxacin in an alkaline solution (pH=12-13) of humates with subsequent introduction into the solution of succinic acid to obtain pH=10-11 and adding propylene glycol to the masses.% 10-30.

Examples of obtaining funds for the treatment of bacterial enteritis in animals:

Table 1
P�emer 1
The name of the componentLimitsCompounding tools
AndEnrofloxacin substance, wt.%0.2 to 1.00,5
BA solution of humates, wt.%70-9080
- humic substances, wt.%0,1-0,50,3
- sodium hydroxide (or potassium hydroxide)to pH=12-13
is succinic acidbefore reaching pH=10-11
InPropylene glycol, wt.%10-30else

Table 2
Example 2
The name of the componentLimits Compounding tools
AndEnrofloxacin substance, wt.%0.2 to 1.00,5
B"Guvitane" TU 9283-00256462103-2010.70-9080
InSodium hydroxide (or potassium hydroxide)to pH=12-13
GSuccinic acidbefore reaching pH=10-11
DPropylene glycol, wt.%10-30else

Table 3
Example 3
The name of the componentLimitsCompounding tools
AndEnrofloxacin substance, wt.%0.2 to 1.00,5
B.�CNY hydrolysate of sapropel with pH=12-13, wt.% (patent RF №2392945)70-9080
InSuccinic acidbefore reaching pH=10-11
GPropylene glycol, wt.%10-30else

Clinical studies:

Example 1

Experience the study of therapeutic effectiveness of the proposed tools in comparison with the known "Enroflon®-10% solution for oral administration" and "Guvitane" was performed on the calves with a diagnosis of acute indigestion, bacterial (bacterial enteritis etiology) aged from 2-3 days up to 1 month at the dairy farms of the Omsk and Tyumen regions. In the experimental group means were given to calves individually inside mixed with milk (colostrum) when feeding once a day at a dose of 1.0 ml per 1 kg of body weight, with a daily dose of the active substance enrofloxacin was 5 mg/kg of body weight of calves. In the 1st control group calves was used for treatment "Enroflon" once a day with liquid feed at a daily dose of 5 mg/kg of body weight. In the 2nd control group "Guvitane" calves injected with liquid feed at 0.8 ml per kg of body weight of 1 times a day.

Analysis of the test results (table 4) St�indicates the best therapeutic efficacy of the developed product. So, in the experience received 100% of therapeutic effect of the use of the proposed funds, and in the control groups, which were respectively applied "Enroflon" and Guvitane", the efficiency was lower and amounted to, respectively, 97% and 56%. In addition, in the experimental group recovery (on the basis of disappearance of the main symptom of the disease - diarrhea) occurred earlier at 34%, and there was no death of animals and the recurrence of the disease. The data obtained indicate that the proposed facility on medical action is superior to "Enroflon" and "Guvitane".

Table 4
Comparative effectiveness of treatment for bacterial enteritis calves proposed facility in comparison with the Enroflon" and "Guvitane"
Indicators of efficiency of treatment of calvesGroups of animals
ExperienceControl 1Control 2
The number of animals in the group, goals4734
The amount of consumed doses of disinfectants tested on 1 calf and / total per group5 (235)5 (170)5 (90)
Came the disappearance of the main symptom of the disease (diarrhea) on average, 1 calf, days2,533,41-
Came the disappearance of the main symptom of the disease (diarrhea) in calves, heads / %:
on the second day, goals / (%)21 /459/270
- on the third day (cumulative number), heads / %39/8317/505/27
- on the fourth day, goals / (%)45/9628/8212/67
- on the fifth day, goals / (%)47/10034/10015/83
Left sick calves, a goal. / %00 3/17
The number of dead animals, heads / %001/6
The number of relapses of the disease, cases / %014/22
Therapeutic efficacy, %1009756

Example 2

Second experience-finding the effectiveness of preventive therapy (drug prevention) the proposed remedy for mass diseases of newborn calves was carried out in comparison with the two drugs, Enroflon" and Guvitane", as well as for General control were taken as statistical data on morbidity and mortality of calves that preventive therapy was not performed, and the causes of disease were similar in all groups: high bacterial contamination of animal pathogenic bacteria of group of an intestinal stick. Subjects funds asked the calves inside with liquid food (milk, colostrum) once daily in the morning feeding for 5 days, starting from the first feeding, doses, calculated as ml/kg body weight: medium - 1; Enroflon - 0.05 and Guvitane and 0.8.

The effectiveness of preventive therapy (table 5) in about�ITE and in two control groups were, respectively, 96%, 93% and 35%, and the ratio of reduction in the incidence of animals covered by groups respectively 11, 6 and 2 times. The results obtained indicate that the application of the proposed tools has a strong preventive action against bacterial enteritis calves and efficiency superior to the "Enroflon" and Guvitane".

Table 5
Preventive therapy (drug prevention) at a mass of bacterial enteritis in neonatal calves (with an incidence of campylobacteriosis in the first 10 days of life - 45% of the number of births)
Performance indicators preventive therapy calvesGroups of animals
ExperienceControl 1Control 2Control total
Tool"Enroflon""Guvitane"Without preventive therapy
The number of animals in the group, goals1205731 60
The amount of consumed doses of disinfectants tested on 1 calf and/ total per group5 (600)5 (285)5 (155)0
Sick calves for 10 days, a goal.54627
The incidence of calves in the first 10 days of life, goals for 100 calves471945
Palo calves, goal0014
The multiplicity of reducing the incidence, time1162-
Preventive effect on 100 calves, a goal.9693350

Analysis of the results of clinical trials proposed remedies for the treatment of pigs, chickens and rabbits, patients with bacterial enteritis, the�showed good therapeutic efficacy. On animals other types of testing not conducted.

Thus, the application of the proposed remedies for the treatment of bacterial enteritis in young farm animals (calves, pigs, chickens, rabbits) has a more pronounced therapeutic effect in comparison with the prototype "Enroflon" and Guvitane".

The tool is simple to use and effective. Its production does not require large expenditures.

Agent for the treatment of bacterial enteritis in animals, for with liquid feed once a day for three to five days at a dose of 0.5 to 1.0 ml per 1 kg of body weight, containing enrofloxacin and excipients, characterized in that it further contains humates from peat or sapropel in the following ratio of components, wt.%: enrofloxacin substance is 0.5; the alkaline solution of humates (pH=12-13) - 80; succinic acid to pH 10-11; propylene glycol - the rest.


Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a strain of the pathogen of pseudomonosis of pigs of the collection of Federal state budgetary institution "VGNKI", deposited under the name "Pseudomonas aeruginosa No.9" and the registration number "No.9-DEP", intended for production of a vaccine against pseudomonosis of pigs.

EFFECT: invention provides high immunogenic activity and the ability of production of the vaccine against pseudomonosis of pigs.

4 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to clinical microbiology and antimicrobial chemotherapy, and concerns developing and creating new combinations providing potentiating bactericidal action and effectively inhibiting the purulent infection caused by methicillin-resistant S. aureus by using two classes of compounds possessing the essentially different mechanism of antimicrobial action.

EFFECT: developing and creating the new combinations providing potentiating bactericidal action and effectively inhibiting the purulent infection.

2 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to polymer ketimine derivatives of doxycycline, which are obtained by condensation of doxycycline hydrochloride with cationic copolymers of acrylamide with 2-ammine-ethyl methacrylate (MW=16-20 kDa) with a molar ratio of copolymer/antibiotic equal to 1.1-2.0/1 in aqueous solution with pH 8.0 at 23°C. where: m=(78.0-80.0) mol %; n=(10.0-14.0) mol.%; k=(6.0-12.0) mol %.

EFFECT: polymer ketimine derivatives of doxycycline, which are non-toxic and combine the antimicrobial and immunosuppressive properties.

2 cl, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a peptide, a peptide mimetic or an amino acid derivative, which contain di-substituted β-amino acid, wherein each of substituting group in the β-amino acid, which can be identical or different, contains at least 7 non-hydrogen atoms, is lipophilic and contains at least one cyclic group; one or more cyclic groups in the substituting group can be bound or condensed with one or more numbers of cyclic groups in the other substituting groups, and when the cyclic groups are fused so that an aggregate total number of non-hydrogen atoms for these two substituting groups makes at least 12, wherein the above peptide, peptide mimetic or amino acid derivative consist of 1-4 amino acids or length-equivalent sub-units.

EFFECT: preparing the peptide, peptide mimetic or amino acid derivative, which contain the di-substituted β-amino acid.

17 cl, 4 dwg, 10 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics and medicine and deals with the application of cysteamine in the treatment of a microbial infection, caused by a microbial biofilm, as well as to a product, containing at least two anti-biofilm agents, where at least one anti-biofilm agent represents an antimicrobial peptide, and the second anti-biofilm agent represents cysteamine. Also claimed are the application of the said product in the treatment of a microbial infection and a method of preventing the formation of the microbial biofilm in a medium.

EFFECT: group of inventions provides higher antibacterial activity in comparison with the activity of any compound separately.

13 cl, 33 dwg, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry, specifically to bensyl aralkyl ether of formula or to its pharmaceutically acceptable salt, where: Ar represents imidazolil; R1, R2, R4 and R5 independently stand for hydrogen; R3 stands for a halogen; R6 stands for trifluoromethyl or trichloromethyl; n is an integer from 0 to 2; and m is 1. The invention also relates to the use of the compound of formula (1) for the treatment and/or prevention of diseases caused by fungi, or bacteria.

EFFECT: obtained new heterocyclic compounds with useful biological properties.

4 cl, 4 dwg, 9 tbl, 8 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration of the tylosin-containing preparation at a dose of 0.05 ml/kg body weight once a day for 3-4 days in all forms of mastitis. The tylosin-containing preparation is used as the preparation of the following composition, wt %: colistin sulphate - 4.0-6.0; tylosin base - 4.0-6.0; benzyl alcohol - 4.0; water for injection - 15.0; 1,2-propylene glycol - 100.0%.

EFFECT: use of the claimed invention enables to improve the therapeutic efficacy of treatment of mastitis.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.

EFFECT: reducing the length of treatment up to 14 days with no side effects.

4 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of probiotic preparation "Prolam" from the first day of life of calves daily for seven days for 5÷7 cm3 orally with colostrum or milk. During prenatal development of calves the probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574) is administered intravaginally to pregnant cows every day for 5-7 days with an interval of 24 hours prior to calving in a dose of 100 cm3.

EFFECT: method is highly effective for prevention of gastrointestinal diseases of newborn calves.

5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics. A medication represents derivatives of glutarimides of the general formula (I) or their pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions and a method of treatment.

EFFECT: ensured by the application of non-toxic derivatives of the said glutarimides for the treatment of eosinophilic diseases, mainly of an allergic origin.

16 cl, 12 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to neuronal health, neuronal protection and neuronal development, and refers to using a composition containing lactoferrin in the concentration of at least 0.1 g/100 kcal of the composition for treating or preventing diseases related to retarded enteral nervous system and/or disturbed enteral nervous system. The composition is specified in a group consisting of food products, products for animals, pharmaceutical compositions, nutrient formulations, nutrieceuticals, drinks, biologically active food additives, baby's formulas. The composition can additionally contain a protein source, a lipid source and a carbon source. The composition is administered into pregnant women, nursing mothers, premature and mature newborn children, infants, toddlers, children and/or adolescents.

EFFECT: preparing the composition for neuronal protection.

14 cl, 1 ex, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining GLP-2 analogues, and can be used in medicine for treating GLP-2-associated disorders. The analogues of GLP-2 with agonistic activity with respect to GLP-2 receptors have been obtained.

EFFECT: invention makes it possible to increase resistance to proteases, which provides the lower clearance of the obtained analogues and prolongation of their bioavailability in comparison with native GLP-2.

29 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: neonatal young pig's liver is homogenised with water; the homogenate is centrifuged for nuclear settlement; the supernatant is heated, centrifuged again; the cooled supernatant is added with cooled ethanol and centrifuged 15-17 h later; the supernatant is dealcoholised; the produced target product is frozen and stored until used in certain environment.

EFFECT: method enables producing the substance stimulating the injured liver repair.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. Presented is the bacteriocin producing strain Lactobacillus pentosus DSM 21980. The strain is used as a therapeutic agent for controlling gram-negative bacteria, preferentially Enterococci, Coliform bacteria, E. coli, reducing or inhibiting the presence thereof. What is also presented is using the strain for the preventive or curative treatment of gastroenteritis or gastoenterocolitis, infections caused by the above bacteria. The strain can be used as an ingredient of the pharmaceutical composition used as a therapeutic agent. Besides, the strain is used as an ingredient of the food composition applicable as a processing additive added to a starter culture for producing dairy products.

EFFECT: group of inventions provides inhibiting the gram-negative bacteria, preferentially E coli.

15 cl, 4 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a citrate of a compound described by formula (II) below, and a pharmaceutical composition containing said citrate.

EFFECT: experimental results of the present inventions prove that said citrate can inhibit activity of phosphodiesterase type 5 and can be used for treating erectile dysfunction, for inhibiting thrombocyte aggregation and treating thrombosis, for reducing pulmonary hypertension and treating cardiovascular diseases, asthma and diabetic gastroparesis.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be used for the treatment of chronic constipation and functional anorexia. For this purpose, as medicinal nutrition used is a milk-vitamin mixture with the following composition (g per 100 g of the product): Proteins 24-26, Fats 27-29, Carbohydrates 33-34, minerals (mg per 100 g of the product), calcium 940-970, phosphorus 780-820, sodium 230-270, potassium 1370-1550, chloride 1270-1350, magnesium 100-125, iron 9.5-10.7, zinc 2.7-3.5, iodine 145-173, copper 76-87, manganese 45-52, vitamins (mcg per 100 g of the product) D3 7.6-8.2, E 6.2-6.8, C 42-46, B1 960-990, B2 1150-1250, Niacin11-15, B6 1370-1440, Folic acid 125-150, Pantothenic acid 2250-2370, B12 1.5-1.9, Biotin 25-31, Choline 40-45.

EFFECT: invention provides an increase of treatment efficiency.

3 ex

FIELD: veterinary science.

SUBSTANCE: declared are a preparation for treating calves' gastrointestinal diseases and a method of treating using the same. The preparation represents a sterile culture fluid produced by culturing the fungus Trametes pubescens (strain 0663) on standard solid and fluid media with sodium selenite and zinc sulphate additionally included into the nutrient medium; that is following by lyophilisation. A method of treating involves adding the preparation to feeding milk. The preparation is introduced in a dose of 180-300 mg per 1 kg of animal's body weight once a day for 4-5 days.

EFFECT: high therapeutic effect of the preparation.

3 cl, 18 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: method includes milling glauconite with the content of rock from 20 to 95%, selection of a fraction of 1.0-10 mcm, preparation of a 40-80% suspension of glauconite in water. The obtained suspension is processed by ultrasound with a frequency of 15-25 kHz for 2-5 minutes. As a result obtained is a glauconite-based enterosorbent, which represents a 40-80% suspension of the glauconite 1.0-10 mcm fraction in water.

EFFECT: obtaining the glauconite-based enetrosorbent, which has the increased sorption ability in the form of a stable water suspension of glauconite.

2 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: erythrocyte cell medium is added with an aqueous solution of sodium and potassium salts of humic acids prepared on brown coal of leonardite in a dose of 10.0 mg/kg. That is incubated at a temperature of 37°C for 40 minutes before treatment with acidic haemolytic.

EFFECT: invention enables normalising the cell membrane permeability and reducing the damaged cell count under acidic haemolytic.

1 tbl